Advertisement

What Are the Complications of Home IBD Medications?

  • Kathryn VossEmail author
Chapter
First Online:

Abstract

Inflammatory bowel disease may be treated with a variety of medications depending on the severity of disease, location of disease, and goals of treatment. Common medications include systemic and local glucocorticoids, antibiotics, 5-aminosalicylates, immunomodulatory agents, and biologic therapies. Each medication class carries distinct and important side effects.

Keywords

Glucocorticoids Antibiotics Aminosalicylates Immunomodulators Biologics Inflammatory bowel disease Side effects Adverse drug reactions 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Curtis J. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420–6.CrossRefGoogle Scholar
  2. 2.
    Etminan M. Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study. Neurology. 2014;83(14):1261.CrossRefGoogle Scholar
  3. 3.
    Khaliq Y. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis. 2003;36(11):1404.CrossRefGoogle Scholar
  4. 4.
    Kang J. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol. 2001;59(1):122–6.CrossRefGoogle Scholar
  5. 5.
    Carroll M. Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2013;57(8):3903–9.CrossRefGoogle Scholar
  6. 6.
    Deshpande A. Community-associated clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother. 2013;68(9):1951.CrossRefGoogle Scholar
  7. 7.
    Box SA. Sulphasalazine in the treatment of rheumatoid arthritis. Br J Rheumatol. 1997;36(3):382–6.CrossRefGoogle Scholar
  8. 8.
    Farr M. Side effect profile of 200 patients with inflammatory arthritides treated with sulphasalazine. Drugs. 1986;32(Suppl 1):49–53.CrossRefGoogle Scholar
  9. 9.
    Schroeder K. Is mesalamine safe? Gastroenterol Hepatol (NY). 2007;3(11):878–9.Google Scholar
  10. 10.
    Chaparro M. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis. 2013;19(7):1404–10.CrossRefGoogle Scholar
  11. 11.
    Beaugerie L. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–25.CrossRefGoogle Scholar
  12. 12.
    Te HS. Hepatic effects of long-term methotrexate use in treatment of inflammatory bowel disease. Am J Gastroenterol. 2000;95(11):3150.CrossRefGoogle Scholar
  13. 13.
    Burdmann EA. Cyclosporine nephrotoxicity. Semin Nephrol. 2003;23(5):465–76.CrossRefGoogle Scholar
  14. 14.
    Hoorn EJ. The cacineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med. 2011;17(10):1304–9.CrossRefGoogle Scholar
  15. 15.
    Eidelman BH. Neurologic complications of FK 506. Transplant Proc. 1991;23(6):3175–8.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Randomized trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet. 1994;344(8920):423–8.Google Scholar
  17. 17.
    Hojo M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999;397(6719):530–4.CrossRefGoogle Scholar
  18. 18.
    Strangfield A. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;70(11):1914–20.CrossRefGoogle Scholar
  19. 19.
    Cheifetz A. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenerol. 2003;98(6):1315–24.CrossRefGoogle Scholar
  20. 20.
    Hastings R. Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken). 2010;62(6):764.CrossRefGoogle Scholar
  21. 21.
    Cleynen I. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med. 2016;164(1):10–22.CrossRefGoogle Scholar
  22. 22.
    Gabriel SE. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis? Arthritis Rheum. 2008 Mar;58(3):637–40.CrossRefGoogle Scholar
  23. 23.
    Dreyer L. Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish multiple sclerosis registry. Ann Rheum Dis. 2016;75(4):785–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.MedStar Georgetown University and Washington Hospital CenterWashington, DCUSA

Personalised recommendations

Cite chapter

Buy options